Kestrel Therapeutics
Boston, Massachusetts, United States · Biotechnology · 28 employees
Kestrel is discovering and developing new molecules to treat intractable cancers. We are starting with potent inhibitors of pan-oncogenic-RAS. We rely on exceptional science, and our focus, always, is on patients.
Funding history
- Venture - Series Unknown — $5.0M — Aug 2025
- Venture - Series Unknown — $8.0M — Feb 2025
- Venture - Series Unknown — $7.5M — Jan 2022
Recent signals
- Aug 12, 2025: Raised $5.0M in Venture - Series Unknown
- Feb 21, 2025: Raised $8.0M in Venture - Series Unknown
- Jan 11, 2022: Raised $7.5M in Venture - Series Unknown
See plans & pricing → Track Kestrel Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.